




2020

Q3 Revenue

Webcast | October 28, 2020





This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but that may not prove to be accurate. By their nature, forward-looking statements involve risk and uncertainty. Consequently the company cannot guarantee their accuracy and their completeness, and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of.


For additional information concerning important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the ‘Autorité des Marchés Financiers’.

Any forward-looking statement speaks only as of the date on which it is made, and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

2020

Q3 - Revenue


The Big Picture



2020

Q3 - Revenue



Q3 2020 Revenue overview



2020

Q3 - Revenue



9M 2020 Revenue overview



2020

Q3 - Revenue

Health Insurance, HR & E-Services Division Overview



COMMENTS

The third-quarter performance was primarily the result of growth at:



- [Cegedim Health Data](#) (healthcare sector data and analytics),
- [Cegedim e-business](#) (document and process digitization),
- [Cegedim SRH](#) (HR management solutions).

[BPO businesses](#) returned to 2019 levels, **but** [project-based business in the health insurance sector](#) continues to experience delays.

2020

Q3 - Revenue

Healthcare Professionals Division Overview



COMMENTS

The third-quarter performance was chiefly attributable to growth at :

- **RM Ingénierie** (computerization of allied health professionals in France),
- **UK doctor computerization** business (owing to specific projects carried out with the NHS),
- **RESIP** (BCB medication database),
- **Maiia's teleconsultation business**.

Doctor computerization activities in France, Spain, and Belgium continue to operate at roughly the same level as in 2019.

2020

Q3 - Revenue

FY 2020 Outlook



Revenue Trend (LfL)

- H1 revenue **fell** by 2.5%
- Q3 revenue **up** 1.9%
- 9M revenue **fell** by 1.1%

FY-2020 outlook

Owing to the spike in Covid-19 cases and the severe tightening of public health restrictions, **we are unable to confirm the Group's 2020 outlook.**

Notice

The Group does not expect any material acquisitions in 2020 and does not provide earnings estimates or forecasts.

2020
Q3 - Revenue

Save the date
December 15, 2020 at 2:30pm CET



V C M D

VIRTUAL # CAPITAL # MARKETS # DAY

2020

For the first time, this event will take place entirely virtually owing to the Covid-19 pandemic.

More details to follow.

Registration is now open at:
<https://bit.ly/3ok1t4G>

Virtual Post-CMD roadshow
on December 17 at 4pm CET
Group call



2020
Q3 - Revenue

Annexes

2020

Q3 - Revenue

Q1 2020 Revenue



| In € thousands | Division 1 | Division 2 | Division 3 | Group |
|--|---------------|---------------|------------|----------------|
| 2019 REVENUE (a) | 79,239 | 39,100 | 882 | 119,222 |
| Impact of disposals | 0 | (2,806) | 0 | (2,806) |
| 2019 Revenue before impact of disposals | 79,239 | 36,294 | 882 | 116,415 |
| Currency impact | 22 | 91 | 0 | 113 |
| 2019 Revenue at 2020 exchange rate (b) | 79,261 | 36,386 | 882 | 116,529 |
| 2020 Revenue before impact of acquisitions (c) | 81,639 | 37,977 | 852 | 120,467 |
| Revenue from acquisitions | 1,029 | 0 | 0 | 1,029 |
| 2020 Revenue | 82,667 | 37,977 | 852 | 121,496 |
| Organic growth [(c-b)/a] | +3.0% | +4.1% | (3.4)% | +3.3% |

2020

Q3 - Revenue

Q2 2020 Revenue



| In € thousands | Division 1 | Division 2 | Division 3 | Group |
|--|---------------|---------------|------------|----------------|
| 2019 REVENUE (a) | 83,260 | 42,472 | 842 | 126,574 |
| Impact of disposals | 0 | (2,778) | 0 | (2,778) |
| 2019 Revenue before impact of disposals | 83,260 | 39,694 | 842 | 123,795 |
| Currency impact | (33) | (160) | 0 | (193) |
| 2019 Revenue at 2020 exchange rate (b) | 83,227 | 39,534 | 842 | 123,603 |
| 2020 Revenue before impact of acquisitions (c) | 76,458 | 36,170 | 878 | 113,506 |
| Revenue from acquisitions | 1,197 | 0 | 0 | 1,197 |
| 2020 Revenue | 77,655 | 36,170 | 878 | 114,703 |
| Organic growth [(c-b)/a] | (8.1)% | (7.9)% | +4.2% | (8.0)% |

2020

Q3 - Revenue

Q3 2020 Revenue



| In € thousands | Division 1 | Division 2 | Division 3 | Group |
|--|---------------|---------------|------------|----------------|
| 2019 REVENUE (a) | 79,585 | 38,014 | 836 | 118,435 |
| Impact of disposals | 0 | (1,618) | 0 | (1,618) |
| 2019 Revenue before impact of disposals | 79,585 | 36,396 | 836 | 116,818 |
| Currency impact | (19) | (75) | 0 | (94) |
| 2019 Revenue at 2020 exchange rate (b) | 79,566 | 36,321 | 836 | 116,724 |
| 2020 Revenue before impact of acquisitions (c) | 80,860 | 37,120 | 959 | 118,939 |
| Revenue from acquisitions | 0 | 0 | 0 | 0 |
| 2020 Revenue | 80,860 | 37,120 | 959 | 118,939 |
| Organic growth [(c-b)/a] | +1.6% | +2.1% | +14.7% | 1.9% |

2020

Q3 - Revenue

9M 2020 Revenue

| In € thousands | Division 1 | Division 2 | Division 3 | Group |
|--|----------------|----------------|--------------|----------------|
| 2019 REVENUE (a) | 242,084 | 119,586 | 2,561 | 364,231 |
| Impact of disposals | 0 | (7,202) | 0 | (7,202) |
| 2019 Revenue before impact of disposals | 242,084 | 112,384 | 2,561 | 357,028 |
| Currency impact | (30) | (143) | 0 | (173) |
| 2019 Revenue at 2020 exchange rate (b) | 242,054 | 112,241 | 2,561 | 356,855 |
| 2020 Revenue before impact of acquisitions (c) | 238,957 | 111,267 | 2,689 | 352,913 |
| Revenue from acquisitions | 2,225 | 0 | 0 | 2,225 |
| 2020 Revenue | 241,183 | 111,267 | 2,689 | 355,138 |
| Organic growth [(c-b)/a] | (1.3)% | (0.8)% | +5.0% | (1.1)% |



Thank you for your attention

Jan Eryk Umiastowski
Chief Investment Officer - Head of Investor Relations

janeryk.umiastowski@cegedim.com
Tel: 00 33 1 49 09 33 36 - Mob: 00 33 6 73 25 96 34

Design: Group Communication Service